|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...345678910111213...39313932» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases, Discordant: Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring. (Pubmed Central) - Oct 1, 2024
For patients with metastatic triple-negative breast cancer (TNBC), treatment with pembrolizumab is dependent on the accurate determination of programmed death ligand 1 (PD-L1) expression using immunohistochemistry (IHC)...In conclusion, concordance between E1L3N and 22C3 testing using CPS for PD-L1 in metastatic TNBC was >90%. However, certain cases were challenging to agree upon using current threshold criteria, highlighting the need for more standardized evidence-based methods to assess PD-L1 expression.
- Rituxan (rituximab) / Roche
Observational data, Journal: Outcome of Relapsed or Refractory Diffuse Large B-cell Lymphoma with Second-line Chemotherapy Ifosfamide-Carboplatin-Etoposide with or without Rituximab. (Pubmed Central) - Oct 1, 2024
However improvement of salvage efficacy is an urgent need with new drugs. Further studies are necessary to determine whether this regimen will improve outcomes of relapsed or refractory diffuse large B-cell lymphoma patients.
- | Tevimbra (tislelizumab-jsgr) / BeiGene
Journal: Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Oct 1, 2024
Further studies are necessary to determine whether this regimen will improve outcomes of relapsed or refractory diffuse large B-cell lymphoma patients. The combination of TACE and tislelizumab, with or without targeted therapy, demonstrated promising efficacy and safety in unresectable HCC, especially in immunotherapy-naive patients, warranting further prospective validation studies.
- || Tyvyt (sintilimab) / Eli Lilly
Review, Journal: Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review. (Pubmed Central) - Oct 1, 2024
To facilitate an early diagnosis, regular monitoring is required during sintilimab treatment. We should also focus on the prevention and management of adverse effects related to steroid use.
- || Retrospective data, Review, Journal, Metastases: Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Oct 1, 2024
In terms of OS, PEM+EV was significantly better than nivolumab plus platinum-based chemotherapy (NIVO+platinumCT) (HR=0.60; 95% CI: 0.45-0.81), PEM+platinumCT (HR=0.55; 95%CI: 0.42-0.72), atezolizumab (ATE) + platinumCT (HR=0.57; 95%CI: 0.43-0.75) and platinumCT (HR=0.47; 95%CI: 0.38-0.58)...The adverse events of grade 3 or higher in immunotherapy (ATE, PEM, durvalumab) was significantly lower than other treatment measures...The adverse events of grade 3 or higher of ATE was the lowest. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024525372, identifier CRD42024525372.
- | Tyvyt (sintilimab) / Eli Lilly
Journal: Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis. (Pubmed Central) - Oct 1, 2024
Glucocorticosteroids are the first-line agents for irAEs. The incidence of rheumatic irAEs may be higher in reality, which will inevitably become a new challenge for rheumatologists and dermatologists.
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report. (Pubmed Central) - Oct 1, 2024
The incidence of rheumatic irAEs may be higher in reality, which will inevitably become a new challenge for rheumatologists and dermatologists. Patients with inoperable huge HCC with PVTT could be converted to SIRT first and accept surgery sequentially.
- | MK-2206 / Merck (MSD), Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (clinicaltrials.gov) - Oct 1, 2024
P2, N=647, Completed, Sponsor: National Cancer Institute (NCI)
Patients with inoperable huge HCC with PVTT could be converted to SIRT first and accept surgery sequentially. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
- || Vesanoid (tretinoin) / Roche, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion: 16-1080.cc: Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=26, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Journal, Immunomodulating: Immunomodulatory treatment may change functional and structural brain imaging in severe mental disorders. (Pubmed Central) - Oct 1, 2024
VBM analysis identified two clusters with increased grey matter volumes (GMV) after rituximab, one in right insula overlapping one of the seed regions with significant rsFC changes. This pilot study implies that rituximab may influence both brain structure and connectivity and that GMV changes and rsFC changes are regionally associated.
- | Rituxan (rituximab) / Roche
Journal: Long-Term Recurrence-Free Survival of an Elderly Patient With Diffuse Large B-cell Lymphoma in the Setting of Rituximab-Containing Therapy and a Natural History of Gastric Adenocarcinoma. (Pubmed Central) - Oct 1, 2024
She eventually passed away, and the autopsy revealed that multiple tumors were not lymphoma, but adenocarcinoma. This case report is a valuable addition to the literature as it analyzes whether rituximab-containing minimum chemotherapy is effective for elderly DLBCL and delineates the natural history of gastric cancer.
- || Rituxan (rituximab) / Roche
Review, Journal: Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review. (Pubmed Central) - Oct 1, 2024
Mycophenolate showed comparable efficacy to cyclophosphamide but with fewer side effects, making it a well-tolerated alternative. The findings of this systematic review will provide valuable insights into the comparative efficacy of rituximab, cyclophosphamide, and mycophenolate in the management of ILD in systemic sclerosis, informing clinical decision-making and guiding future research in this area.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma. (Pubmed Central) - Oct 1, 2024
This case highlights the critical need for vigilant monitoring and prompt management of neurologic and cardiac irAEs in patients undergoing ICI therapy. Clinicians should maintain a high index of suspicion for MG and myocarditis to improve diagnostic accuracy and patient outcomes.
- || HX-009 / Waterstone Hanxbio, HanX Biopharma
Trial completion date, Trial primary completion date: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=99, Recruiting, Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd.
Clinicians should maintain a high index of suspicion for MG and myocarditis to improve diagnostic accuracy and patient outcomes. Trial completion date: Aug 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
- || abequolixron (RGX-104) / Inspirna
Trial completion date, Trial primary completion date: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov) - Oct 1, 2024
P1, N=146, Active, not recruiting, Sponsor: Inspirna, Inc.
Trial completion date: Aug 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2025 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- ||||| Imfinzi (durvalumab) / AstraZeneca, Tagrisso (osimertinib) / AstraZeneca
Enrollment closed, Trial primary completion date: PACIFIC-4: Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (clinicaltrials.gov) - Oct 1, 2024
P3, N=724, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Apr 2027
- | SX-682 / Syntrix, Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
New P1 trial: SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 1, 2024
P1, N=15, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- || KYV-101 / Kyverna
Enrollment open: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome (clinicaltrials.gov) - Oct 1, 2024
P2, N=25, Recruiting, Sponsor: Kyverna Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Apr 2027 Not yet recruiting --> Recruiting
- ||| tobemstomig (RG6139) / Roche, tiragolumab (RG6058) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Oct 1, 2024
P2, N=210, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2024 --> May 2025
- || Bavencio (avelumab) / EMD Serono
Enrollment closed: MS100070_0087: Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors (clinicaltrials.gov) - Oct 1, 2024
P1, N=50, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2024 --> May 2025 Recruiting --> Active, not recruiting
- || Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis. (Pubmed Central) - Oct 1, 2024
Studies with low risk of bias did not support repurposing TNF inhibitors, tocilizumab, abatacept or tofacitinib for dementia prevention, but hydroxychloroquine may be a potential candidate. Further studies that carefully mitigate important sources of biases are warranted, and long-term evidence will be preferred.
- | sunitinib / Generic mfg.
Journal: Oral delivery of Sunitinib malate using carboxymethyl cellulose/poly(acrylic acid-itaconic acid)/Cloisite 30B nanocomposite hydrogel as a pH-responsive carrier. (Pubmed Central) - Oct 1, 2024
Further studies that carefully mitigate important sources of biases are warranted, and long-term evidence will be preferred. High anticancer activity of Hyd/Cloisite 30B against MCF-7 human breast cancer cells was shown by the MTT assay, with a MCF-7 cell viability of 23.82?
- | Yutuo (zimberelimab) / Arcus Biosci, Gilead, etrumadenant (AB928) / Arcus Biosci, Gilead
Trial completion date: PANTHER: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. (clinicaltrials.gov) - Oct 1, 2024
P2, N=43, Recruiting, Sponsor: Weill Medical College of Cornell University
High anticancer activity of Hyd/Cloisite 30B against MCF-7 human breast cancer cells was shown by the MTT assay, with a MCF-7 cell viability of 23.82? Trial completion date: Dec 2027 --> Dec 2030
- || Rituxan (rituximab) / Roche
Review, Journal: Monoclonal antibodies for inflammatory, autoimmune and oncological skin diseases (Pubmed Central) - Oct 1, 2024
Trial completion date: Dec 2027 --> Dec 2030 In 1997 rituximab, a
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Adverse events, Gene Signature, PD(L)-1 Biomarker, IO biomarker, Immune cell: Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma. (Pubmed Central) - Oct 1, 2024
This finding aligns with our previous work linking anti-CTLA-4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3-5 irAE risk, which is especially important in AT.
- | quemliclustat (AB680) / Arcus Biosci, Gilead
Journal: Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. (Pubmed Central) - Oct 1, 2024
To test our hypothesis, we used the KrasG12D; PdxCre1 (KC) genetically engineered mouse model and tested the utility of AB-680, a small molecule inhibitor targeting CD73, to inhibit PanIN progression...The scRNA-seq analysis showed that CD73 inhibition reduced M2 macrophages, acinar, and PanIN cell populations. CD73 inhibition enhanced immune surveillance and expanded unique clonotypes of TCR and BCR, indicating that inhibition of CD73 augments adaptive immunity early in the neoplastic microenvironment.
- | Journal: Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report. (Pubmed Central) - Oct 1, 2024
The case was notable for reporting a not-yet described adverse event during treatment with belzutifan plus lenvatinib, the etiology of which was of unobvious determination given the pre-exposure to pembrolizumab, a known cause of drug-related myocarditis. We surmise that myocarditis was a delayed adverse event related to pembrolizumab (8
- | Bavencio (avelumab) / EMD Serono
Biomarker, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Biomarker analyses investigating disease biology and associations with outcomes in the JAVELIN Merkel 200 trial of avelumab in metastatic Merkel cell carcinoma. (Pubmed Central) - Oct 1, 2024
Exploratory analyses provide insights into mMCC biology and potential associations with response to avelumab. Chemotherapy seems to negatively modulate the immune microenvironment.
- || Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date, Combination therapy: CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 1, 2024
P1, N=121, Recruiting, Sponsor: Hoffmann-La Roche
Chemotherapy seems to negatively modulate the immune microenvironment. Trial completion date: Mar 2029 --> Jul 2028 | Trial primary completion date: Mar 2027 --> Jul 2026
- | Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
Trial completion date, Trial primary completion date: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara (clinicaltrials.gov) - Oct 1, 2024
P2, N=401, Active, not recruiting, Sponsor: Stichting European Myeloma Network
Trial completion date: Mar 2029 --> Jul 2028 | Trial primary completion date: Mar 2027 --> Jul 2026 Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: May 2024 --> Jun 2025
- ||| SAR443579 / Sanofi
Enrollment change, Trial completion date: TCD17197: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=169, Recruiting, Sponsor: Sanofi
Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: May 2024 --> Jun 2025 N=126 --> 169 | Trial completion date: Nov 2026 --> Oct 2030
- | Verzenio (abemaciclib) / Eli Lilly
New trial: Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29) (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=30, Recruiting, Sponsor: University Hospital, Brest
- ||||| izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
New P1/2 trial: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=218, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||||||||| Ariely (adebrelimab) / Jiangsu Hengrui Pharma, SHR-8068 / Jiangsu Hengrui Pharma
New P3 trial: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 1, 2024
P3, N=560, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- ||| Benlysta (belimumab) / GSK
Enrollment change: REBOOT: Belimumab With Rituximab for Primary Membranous Nephropathy (clinicaltrials.gov) - Oct 1, 2024
P2, N=58, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=126 --> 169 | Trial completion date: Nov 2026 --> Oct 2030 N=124 --> 58
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Endostar (recombinant human endostatin) / Simcere
New P2 trial: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (clinicaltrials.gov) - Oct 1, 2024
P2, N=35, Recruiting, Sponsor: Hua Zhang
- | Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date: ARION: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (clinicaltrials.gov) - Oct 1, 2024
P2, N=112, Active, not recruiting, Sponsor: UNICANCER
N=124 --> 58 Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- |||||| Kisqali (ribociclib) / Novartis
New trial: Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=194, Completed, Sponsor: Novartis Pharmaceuticals
- ||| daxdilimab (HZN-7734) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) (clinicaltrials.gov) - Oct 1, 2024
P2, N=12, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Recruiting --> Active, not recruiting | N=96 --> 12 | Trial completion date: May 2027 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Mar 2025
- ||||| Brukinsa (zanubrutinib) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date: ARIADNE: Zanubrutinib in Patients With Waldenstr (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=605, Recruiting, Sponsor: iOMEDICO AG
Recruiting --> Active, not recruiting | N=96 --> 12 | Trial completion date: May 2027 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Mar 2025 N=400 --> 605 | Trial completion date: Apr 2027 --> Aug 2028 | Trial primary completion date: Apr 2027 --> Aug 2028
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Tumor mutational burden: BTCRC-LUN18-153: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm (clinicaltrials.gov) - Oct 1, 2024
P2, N=244, Recruiting, Sponsor: Greg Durm, MD
N=400 --> 605 | Trial completion date: Apr 2027 --> Aug 2028 | Trial primary completion date: Apr 2027 --> Aug 2028 Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2025 --> Apr 2026
- || Reqorsa (quaratusugene ozeplasmid) / Genprex
Trial completion date, Trial primary completion date, Combination therapy: Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov) - Sep 30, 2024
P1/2, N=180, Active, not recruiting, Sponsor: Genprex, Inc.
Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2025 --> Apr 2026 Trial completion date: Nov 2028 --> Dec 2025 | Trial primary completion date: Nov 2027 --> Dec 2024
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date, Metastases: CAPSTONE: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (clinicaltrials.gov) - Sep 30, 2024
P2, N=28, Recruiting, Sponsor: Qian Chu
Trial completion date: Nov 2028 --> Dec 2025 | Trial primary completion date: Nov 2027 --> Dec 2024 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial. (Pubmed Central) - Sep 30, 2024
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Neoadjuvant camrelizumab plus chemotherapy is effective for locally advanced, resectable ESCC, eliciting profound immune response that closely associated with clinical outcomes.
- || BCMA-CD19 cCAR T cells / iCell Gene Therap
P1 data, Journal, CAR T-Cell Therapy: BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. (Pubmed Central) - Sep 30, 2024
Neoadjuvant camrelizumab plus chemotherapy is effective for locally advanced, resectable ESCC, eliciting profound immune response that closely associated with clinical outcomes. Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.
- | Rituxan (rituximab) / Roche
Journal: Top 10 Clinical Pearls in Vasculitic Neuropathies. (Pubmed Central) - Sep 30, 2024
Frequently, other specialists such as rheumatologists, pulmonologists, and nephrologists will comanage these complex patients with systemic vasculitis. Prompt recognition of these conditions is imperative, as delays in treatment may result in permanent deficits and even death.
- | Rituxan (rituximab) / Roche
Retrospective data, Journal: Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS. (Pubmed Central) - Sep 30, 2024
Serious infection rates were lower in the RTX group than in the non-RTX group, with no statistically significant difference. RTX was not superior to conventional immunosuppressive therapies at week 24 but showed significantly favourable results at week 48 for severely relapsed AAV.
- | naratuximab emtansine (DEBIO 1562) / Debiopharm
Journal: CD37 in acute myeloid leukemia: a novel surface target for drug delivery. (Pubmed Central) - Sep 30, 2024
We found that ?CD37-DM1 improved clinical outcomes and overall survival in multiple in vivo models of AML. Together, these data demonstrate that targeting CD37 with an ADC such as ?CD37-DM1 is a feasible and promising therapeutic option for the treatment of AML.
- | Nulojix (belatacept) / BMS
Journal: Belatacept Versus Tacrolimus for Kidney Transplant Recipients of Deceased Donors With Acute Kidney Injury: Glass Half-Full? (Pubmed Central) - Sep 30, 2024
Together, these data demonstrate that targeting CD37 with an ADC such as ?CD37-DM1 is a feasible and promising therapeutic option for the treatment of AML. No abstract available
- | Nplate (romiplostim) / Amgen, Promacta (eltrombopag) / Novartis
Journal: Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies. (Pubmed Central) - Sep 30, 2024
In conclusion, TPO-RAs appeared as an effective and safe option of treatment in these case series. Our results suggest that Eltrombopag or Romiplostim should be considered as second line therapy of ITP related to predominantly antibody deficiencies.